IVD (In Vitro Diagnostics)
The LUMIPULSE® Series Has Supported Testing for Over 25 years
The LUMIPULSE Series, a fully automatic chemiluminescent enzyme immunoassay system, has been highly regarded among medical institutions and testing centers for over 25 years due to its high quality and performance, as well as a wide range of reagent lineups capable of accommodating infectious disease, cancer, and lifestyle disease patients. Over 2,300 LUMIPULSE devices support medical institutions and testing centers domestically and abroad, truly making it “the world’s LUMIPULSE.” Domestically, we have been providing it as a combination device with the highperformance LUMIPULSE L2400 since 2017. We will continue to contribute to optimizing and accelerating testing.
Enhancing the Global Structure and OEM Business
At the H.U. Group, we presently provide products and services to over 100 countries. Fujirebio Holdings, which supervises the entire In Vitro Diagnostics business, will accelerate the implementation of the global strategy in order to provide a world-class leading product lineup. Also, we were quick to develop antigen test reagents for the novel coronavirus by taking advantage of our long years of experience with infectious disease testing.
At our U.S. subsidiary, we develop and manufacture world-class cancer testing products and supply ingredients for test drugs while at our Belgian subsidiary, we develop and manufacture In Vitro Diagnostics for Alzheimer’s disease as a pioneer in the field.
Additionally, we are promoting and enhancing our OEM business with the tripolar business alliance between Fujirebio Diagnostics Japan, Inc., Fujirebio Diagnostics, Inc., and Fujirebio Europe N.V.
ESPLINE® Rapid diagnostics kit series
Fujirebio launched the ESPLINE rapid diagnostics kit series in 1997. Not needing a special testing device, it provides convenient and quick test results, which is why it is the rapid diagnostics kit of choice for influenza, hepatitis B, and the novel coronavirus at hospitals and clinics.